Genfit launches a PhIII study for NASH drug

France's Genfit says it is preparing to launch its Phase III study of the NASH drug elafibranor. The biotech plans to recruit 1,800 patients for the study at 200 centers worldwide. And the company plans to seek an approval based on an interim analysis of the data after 72 weeks. Genfit is pushing ahead shortly after Intercept's ($ICPT) rival OCA failed a Phase II study in Japan. Release